MAIA
$1.50
MAIA Biotechnology, Inc., together with its subsidiaries, immuno-oncology company, focuses on the development and commercialization of drugs with novel mechanisms of action that are intended to improve and extend the lives of people with cancer.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
MAIA Biotechnology, Inc., together with its subsidiaries, immuno-oncology company, focuses on the development and commercialization of drugs with novel mechanisms of action that are intended to improve and extend the lives of people with cancer. Its ...
Recent News
Cancer drug maker takes sudden pivot into crypto
A cancer drug developer has rocked Wall Street by implementing what is perhaps the most audacious crypto treasury strategy we have seen from a traditional biotech firm. MAIA Biotechnology (NYSE American: MAIA) announced on October 7 that its Board of Directors has approved allocating up to 90% of ...
Maia’s NSCLC immunotherapy secures Phase II efficacy win
The biotech is now running a Phase II expansion study to better evaluate the long-term benefits of ateganosine in third-line NSCLC.
MAIA Biotechnology doses first patient in expansion of Phase II lung cancer trial
The study will assess ateganosine in individuals who have been heavily pre-treated in third-line (3L) NSCLC.
MAIA Biotechnology, Roche sign supply agreement for cancer therapies
MAIA Biotechnology (MAIA) announced its entry into a clinical master supply agreement with Roche (RHHBY) for future studies. The agreement will investigate the combination of MAIA’s telomere-targeting agent ateganosine, sequenced with Roche’s checkpoint inhibitor atezolizumab, for the treatment of multiple hard-to-treat cancers. MAIA Chairman and CEO Vlad Vitoc stated that preclinical studies found ateganosine to be highly synergistic with atezolizumab. Published first on TheFly – the ultimate s
MAIA Biotechnology's Experimental Cancer Drug Shows Tripled Survival Vs. Standard Chemotherapy In Pretreated Lung Cancer Patients
MAIA Biotechnology, Inc. (NASDAQ:MAIA) on Thursday revealed updated data from its THIO-101 pivotal Phase 2 clinical trial. The trial is evaluating its lead clinical candidate, ateganosine (THIO), sequenced with Regeneron Pharmaceutical Inc’s (NASDAQ:REGN) immune checkpoint inhibitor (CPI) cemiplimab (Libtayo) for advanced non-small cell lung cancer (NSCLC) who are resistant to immune therapy and chemotherapy. As of May 15, third line (3L) data showed median overall survival (OS) of 17.8 months f